Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07680699 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NEOSENT: Early Anti-PD-1 Therapy In High-Risk Stage II Melanoma

Study acronym: NEOSENT
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This is an observational cohort study evaluating clinical and pathological outcomes in patients with high-risk stage II melanoma. Patients are included after receiving treatment as part of routine clinical practice. Decisions about treatment, including whether to start anti-PD1 therapy before surgery, are made by the treating physician and are not influenced by the study. The study compares outcomes between patients who started anti-PD1 therapy before surgery and those treated according to the usual timing in clinical practice. No treatments are assigned as part of the study.
Trial Details
NCT Number NCT07680699
Lead Sponsor AC Camargo Cancer Center
Conditions
(from sponsor)		 Cutaneous Melanoma
Related terms Melanoma
Enrollment 250 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov